RBC Capital Lifts Insulet (PODD) PT to $365 on Strong Momentum, Q3 Guidance Optimism

Insulet Corporation (NASDAQ:PODD) is one of the best NASDAQ growth stocks to buy for the next 5 years. On October 10, RBC Capital raised the price target on Insulet to $365 from $350 and kept an Outperform rating on the shares as part of a broader research note on the MedTech sector ahead of Q3 2025 results due to attractive valuations and numerous opportunities in the Medical Supplies & Devices sector.

RBC Capital is particularly bullish on Insulet. Investor sentiment is positive ahead of the company’s Q3 earnings report because management has already signaled that strong business momentum will allow them to surpass their official Q3 guidance, which essentially minimizes the risk for the quarter.

RBC Capital Lifts Insulet (PODD) PT to $365 on Strong Momentum, Q3 Guidance Optimism

Additionally, on October 21, Stifel resumed coverage on several MedTech companies with an upbeat outlook driven by the steady adoption of continuous glucose monitors and insulin pumps. In the Insulin Pump segment, Stifel suggested that the Type 2 Insulin-intensive opportunity is significant for pump providers, which, according to the firm, adds to Insulet’s strengths.

Insulet Corporation (NASDAQ:PODD) develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the US and internationally.

While we acknowledge the potential of PODD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PODD and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.